Navigation Links
FluoroPharma, Inc. to Report Preclinical Data on Alzheimer's Disease and Prostate Cancer PET Imaging Agents
Date:9/8/2008

BOSTON, Sept. 8 /PRNewswire/ -- FluoroPharma, Inc. announced today that Dr. David Elmaleh, FluoroPharma's founder and Chief Scientific Advisor, will report on two preclinical studies demonstrating the potential of novel Positron Emission Tomography (PET) molecular imaging agents for detection of Alzheimer's disease (AD) and prostate cancer at the World Molecular Imaging Congress, in Nice, France on September 10-13, 2008.

The first study, "Synthesis And Biodistribution Of 2-(2-[18f]Fluoroethyl)-8-Methyl-2,8-Diazaspiro[4,5]Decane-1,3,-Dione ([18f]Fluoro-RS-86), A Muscarinic Acetylcholine Receptor Agonist" describes the synthesis, tissue distribution and pharmacokinetic profile of 18F labeled RS-86, a known M1 muscarinic receptor agonist. FluoroPharma has developed a novel biomarker approach for evaluating the progression of Alzheimer's disease based on targeting acetylcholine receptors' activity in the brain. As explained by Dr. Elmaleh, "Acetylcholine receptors have become a potential therapeutic target for improving cognitive function, since the receptors' function in patients with AD is impaired due to accumulation of amyloid plaque. In conjunction with PET imaging, FluoroPharma's compound may be a novel approach to the diagnosis of AD and other neurological diseases and the evaluation of new therapeutics."

The second study, "Accumulation Of F-18 Labeled Modified Fatty Acid (CardioPET) In Prostate Tumor Cells: A Potential Sensitive Pet Tracer For Prostate Imaging" explores the potential of CardioPET, a fatty acid analog, to detect prostate cancer. CardioPET concentrates in significant amounts in human prostate tumor cells and shows potential as a highly sensitive agent for detecting prostate cancer. Prostate cancer is the most frequently diagnosed and second most lethal malignancy among men in the United States.

"These new molecular imaging approaches complement FluoroPharma's existing cardiovascular clinical programs and warrant further evaluation", says Dr. Kundakovic, FluoroPharma's President. "We look forward to expanding our discovery and development of molecular imaging pharmaceuticals for PET to meet the growing needs in neurology and oncology."

About FluoroPharma

FluoroPharma, Inc., a privately-held molecular imaging company headquartered in Boston MA, engages in the discovery, development and commercialization of proprietary diagnostic imaging products for the PET market. The company's initial focus is the advancement of three imaging agents -- CardioPET, BFPET, and VasoPET -- for the efficient detection and assessment of acute and chronic forms of coronary artery disease (CAD). Other products in development include agents for the diagnosis of certain types of cancer and for the diagnosis and treatment of Alzheimer's disease. For more information, please visit http://www.fluoropharma.com.

This release may contain forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements reflect, among other things, management's current expectations, plans and strategies, and anticipated financial results, all of which are subject to known and unknown risks, uncertainties and factors that may cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Many of these risks are beyond our ability to control or predict including the company's need for additional funds, the company's dependence on a limited number of imaging compounds, the early state of the products the company is developing, uncertainties relating to clinical trials and regulatory reviews, competition and dependence on collaborative partners, the company's ability to avoid infringement of the patent rights of others, and the company's ability to obtain adequate patent protection and to enforce these rights. Because of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Furthermore, forward-looking statements speak only as of the date they are made. FluoroPharma does not undertake any obligation to update or review any such forward-looking information, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE FluoroPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Society of Interventional Radiology Applauds Reports Uterine Fibroid Embolization Recommendations
2. Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter
3. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
4. Previous Claims of siRNA Therapeutic Effects Called into Question by Report in Human Gene Therapy
5. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
6. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
7. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
8. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
9. Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
10. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
11. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
Breaking Medicine News(10 mins):